Stat3 pathway inhibitors and cancer stem cell inhibitors
The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
1. A compound of formula II,
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof, wherein the symbols have the following meanings and are, for each occurrence, independently selected:
X is O or S;
R 1 is hydrogen, halogen, cyano, nitro, CF 3 , OCF 3 , alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or SR a ;
R 4 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, alkylaryl or substituted alkylaryl;
R 5 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, aryl or substituted aryl, alkylaryl or substituted alkylaryl; optionally, R 4 and R 5 may be combined to form alkenyl or substituted alkenyl;
R 7 is hydrogen, halogen, cyano, nitro, CF 3 , OCF 3 , alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , or SR a ;
R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; and
n is 1-4,
provided that at least one of R 1 , R 4 , R 5 and R 7 is aryl or substituted aryl.
2. The compound of claim 1 , wherein the compound is:
3. A compound of formula III,
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof, wherein the symbols have the following meanings and are, for each occurrence, independently selected:
X is O or S;
R 1 is halogen;
R 4 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, alkylaryl or substituted alkyl aryl;
R 5 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, aryl or substituted aryl, alkylaryl or substituted alkylaryl; optionally, R 4 and R 5 may be combined to form alkenyl or substituted alkenyl;
R 6 is hydrogen, alkyl or substituted alkyl, OR a , OC(═O)R a , or SR a ;
R 7 is hydrogen, halogen, cyano, nitro, CF 3 , OCF 3 , alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , or SR a ; and
R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.
4. A compound having the structure:
5. A pharmaceutical composition comprising a compound as claimed in claim 1 , or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable excipient, carrier, or diluent.
6. A pharmaceutical composition comprising a compound as claimed in claim 3 , or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable excipient, carrier, or diluent.